https://www.selleckchem.com/products/BI-2536.html
22 and the brain to plasma AUC ratio was 2.63. Based on the published human pharmacokinetic data, the anticipated C in humans is expected to be significantly higher than the IC-50 identified in DIPG models. It is expected that panobinostat would be effective in CNS tumors where the IC-50 is in the low nanomolar range. Thus, our data demonstrate panobinostat crosses the BBB and achieves concentrations above the IC-50 for DIPG and other brain tumors and should be explored further for clinical efficacy. It is expected that panobinostat wou
Like
Comment
Share
